EGFR and neoplasm: The median (range) follow-up periods were 15.9 (1.7-68.0) months in the training cohort, 13.5 (1.5-57.0) months in external validation cohort 1, and 11.8 (2.0-55.0) months in external validation cohort 2, and 313 of 342 patients (91.5%) in the EGFR-TKI cohorts experienced tumor progression (29 patients, censored data).